Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CUE Cue Biopharma	$0.80 -3.3%	$0.79	$0.45 ▼ $1.99	$61.33M	1.53	254,683 shs	62,340 shs
IMMX Immix Biopharma	$2.26 +15.3%	$2.49	$1.26 ▼ $3.20	$65.16M	0.28	169,380 shs	422,336 shs
INMB INmune Bio	$2.09 +1.7%	$3.04	$1.89 ▼ $11.64	$55.15M	0.97	1.54 million shs	523,247 shs
NRSN NeuroSense Therapeutics	$1.13 +0.9%	$1.71	$0.68 ▼ $2.60	$15.39M	1.64	241,944 shs	82,625 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CUE Cue Biopharma	-1.19%	+2.67%	+1.18%	+28.88%	+13.84%
IMMX Immix Biopharma	-7.55%	-10.50%	-27.94%	-12.89%	-10.09%
INMB INmune Bio	-5.09%	-13.14%	-29.55%	-72.15%	-70.96%
NRSN NeuroSense Therapeutics	+0.01%	-5.08%	-44.83%	-25.33%	+51.15%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CUE Cue Biopharma	2.5992 of 5 stars	0.0	5.0	4.7	3.0	0.8	0.6
IMMX Immix Biopharma	3.343 of 5 stars	3.3	5.0	0.0	1.9	3.3	0.6
INMB INmune Bio	2.0046 of 5 stars	3.3	2.0	0.0	1.7	1.7	0.6
NRSN NeuroSense Therapeutics	2.346 of 5 stars	3.5	3.0	0.0	2.5	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CUE Cue Biopharma	0.00	N/A	N/A	N/A
IMMX Immix Biopharma	2.50	Moderate Buy	$7.00	209.73% Upside
INMB INmune Bio	2.57	Moderate Buy	$18.40	782.49% Upside
NRSN NeuroSense Therapeutics	3.00	Buy	$14.00	1,138.94% Upside

Current Analyst Ratings Breakdown

Latest NRSN, INMB, CUE, and IMMX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2025	IMMX Immix Biopharma	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/15/2025	NRSN NeuroSense Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
7/10/2025	NRSN NeuroSense Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
7/2/2025	INMB INmune Bio	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $8.00
7/1/2025	INMB INmune Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
7/1/2025	INMB INmune Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Outperform ➝ Sector Underperform
6/30/2025	INMB INmune Bio	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
6/4/2025	IMMX Immix Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CUE Cue Biopharma	$9.29M	6.60	N/A	N/A	$0.24 per share	3.33
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	$0.16 per share	N/A
INMB INmune Bio	$10K	5,541.93	N/A	N/A	$1.09 per share	1.91
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	($0.04) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CUE Cue Biopharma	-$40.67M	-$0.56	N/A	N/A	N/A	-469.35%	-230.13%	-111.16%	11/13/2025 (Estimated)
IMMX Immix Biopharma	-$21.61M	-$0.77	N/A	N/A	N/A	N/A	-205.35%	-110.63%	11/11/2025 (Estimated)
INMB INmune Bio	-$42.08M	-$2.48	N/A	N/A	N/A	N/A	-120.62%	-92.94%	10/30/2025 (Estimated)
NRSN NeuroSense Therapeutics	-$10.21M	-$0.54	N/A	∞	N/A	N/A	N/A	-445.40%	9/29/2025 (Estimated)

Latest NRSN, INMB, CUE, and IMMX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	CUE Cue Biopharma	-$0.13	-$0.09	+$0.04	-$0.09	$2.00 million	$2.95 million
8/8/2025	Q1 2025	IMMX Immix Biopharma	-$0.21	-$0.22	-$0.01	-$0.22	N/A	N/A
8/7/2025	Q2 2025	INMB INmune Bio	-$0.37	-$0.34	+$0.03	-$1.05	$0.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CUE Cue Biopharma	N/A	N/A	N/A	N/A	N/A
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CUE Cue Biopharma	0.01	1.60	1.60
IMMX Immix Biopharma	N/A	1.23	1.23
INMB INmune Bio	N/A	4.20	4.20
NRSN NeuroSense Therapeutics	N/A	0.71	2.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CUE Cue Biopharma	35.04%
IMMX Immix Biopharma	11.26%
INMB INmune Bio	12.72%
NRSN NeuroSense Therapeutics	1.04%

Insider Ownership

Company	Insider Ownership
CUE Cue Biopharma	10.78%
IMMX Immix Biopharma	55.40%
INMB INmune Bio	35.70%
NRSN NeuroSense Therapeutics	27.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CUE Cue Biopharma	60	76.85 million	68.56 million	Optionable
IMMX Immix Biopharma	9	28.83 million	12.86 million	Optionable
INMB INmune Bio	10	26.58 million	17.09 million	Optionable
NRSN NeuroSense Therapeutics	10	13.67 million	9.92 million	Not Optionable

NRSN, INMB, CUE, and IMMX Headlines

Recent News About These Companies

NeuroSense Therapeutics (NASDAQ:NRSN) Trading Up 2.9% - What's Next?

August 23, 2025 | americanbankingnews.com

NeuroSense Therapeutics Ltd. (NRSN) - Yahoo Finance

August 22, 2025 | finance.yahoo.com

NeuroSense Therapeutics Announces Annual General Meeting for September 2025

August 22, 2025 | msn.com

NeuroSense reports 20% of people with ALS from Phase 2a study remain on PrimeC

August 20, 2025 | msn.com

NeuroSense Reports Long-Term Safety of PrimeC in ALS Study

August 20, 2025 | tipranks.com

D. Boral Capital Reaffirms "Buy" Rating for NeuroSense Therapeutics (NASDAQ:NRSN)

August 17, 2025 | americanbankingnews.com

NeuroSense Provides Business Update and Progress for the First Half of 2025

August 1, 2025 | prnewswire.com

Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community

July 22, 2025 | prnewswire.com

NeuroSense Therapeutics Releases Q2 2025 Corporate Update

July 10, 2025 | tipranks.com

Neurosense Therapeutics Ltd News (NRSN) - Investing.com

July 2, 2025 | investing.com

NeuroSense Completes Key Meeting with Health Canada for ALS Drug Approval

June 26, 2025 | tipranks.com

Top Nasdaq Companies by Market Cap Ranked by Kalkine

June 7, 2025 | kalkinemedia.comK

Neurosense, awaiting Canada approval, scales PrimeC production

May 15, 2025 | alsnewstoday.comA

D. Boral Capital Initiates Coverage of NeuroSense Therapeutics (NRSN) with Buy Recommendation

May 14, 2025 | msn.com

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

May 12, 2025 | benzinga.com

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

May 7, 2025 | prnewswire.com

NeuroSense Therapeutics Advances ALS Treatment and Strategic Partnership

April 24, 2025 | tipranks.com

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

April 24, 2025 | prnewswire.com

NeuroSense Therapeutics Presents Promising Phase 2b Data on PrimeC for ALS at AAN Meeting

April 10, 2025 | sohu.comS

NeuroSense Therapeutics Reports Year-End 2024 Financial Results and Provides Business Updates

April 10, 2025 | sohu.comS

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRSN, INMB, CUE, and IMMX Company Descriptions

Cue Biopharma NASDAQ:CUE

$0.80 -0.03 (-3.34%)

As of 03:48 PM Eastern

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Immix Biopharma NASDAQ:IMMX

$2.26 +0.30 (+15.31%)

As of 03:52 PM Eastern

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

INmune Bio NASDAQ:INMB

$2.08 +0.04 (+1.71%)

As of 03:52 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

NeuroSense Therapeutics NASDAQ:NRSN

$1.13 +0.01 (+0.89%)

As of 03:52 PM Eastern

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time